Wall Street analysts expect Agilent Technologies (A) to post quarterly earnings of $1.37 per share in its upcoming report, which indicates a year-over-year increase of 4.6%. Revenues are expected to be $1.8 billion, up 7.2% from the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's earnings release, ...

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无 法看到我们的推送。 骇思 销售工程师 仪粉er们，今天是精品仪器类职位专辑 哦！ 仪器精英，热招职位 Ho t r e c r u itme n t p o siti o n s 销售类 安捷伦 销售工程师 全国有岗-面议 任 职 要 求 ： 硕 士 及 以 上 学 历 ， 制 药 、 食 品 、 环 境 、 化 学 、 生 物 、 材 料 等 相 关 专 业 ； 2025/2026届毕业生，熟练掌握色质谱学科基础理论，有相关产品使用经验；出色的人际交 往能力和沟通能力，团队合作能力强；有明确的自我提升意愿和目标，持续学习能力强。 任职要求： 有志于成为公司未来合伙人；有坚持长期主义的理想信念，有扎根科学仪器行业的 毅力、有拼搏进取的开拓精神；本科及以上学历，性别不限；生物、化学、环境、材料或仪器 分析等相关专业教育背景；3年及以上科学仪器行业相关从业经验，熟悉渠道开发者优先；具 备较强的学习能力、语言表达能力，业务谈判能力；有良好的人际沟通能力和团队协作精神； 富有激情，能承受工作压力；能够适应出差。 ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们 的推送。 张艳丽 鹤壁市产品质量检验检测中心 使 用 气 质 联 用 仪 快 10 年 了 ， 日 常 用 于 农 产 品 中 检 测 农 药 残 留 。 检 测 农 药 残 留 具 有 一 定 的 复 杂 性，一方面，涉及的农药品种繁多，单个样品通常需要检测上百种农药；另一方面，农药残留都 是痕量或超痕量的。为了检得出、检得准，可以说是费尽了心思。 刚开始使用气质联用仪的时候，遇见一系列的问题。为了排查这些问题，从夜不能寐到崩溃。现 在已经用了近 10年了，把这些故障整理了一下，分享给大家。 图 1 ： 气 质 联 用 仪 在使用气质联用仪（ GC-MS）检测农药残留的过程中，常常会遇到一系列故障，例如调谐报告 不通过、进样口压力异常关闭、进样塔无法工作、通讯错误、基线高不出峰、未检测到色谱峰、 色谱峰异常、灵敏度差、样品重复性差以及软件操作故障等。针对这些问题，结合日常实际操作 经验，可以从以下几个方面进行故障排查与仪器的维护保养。 一、 常见故障排除 （一）调谐报告不通过 调谐报告不通过，基本上 ...

Group 1 - The article promotes a subscription service for the Bloomberg Dividend Focus 50, highlighting its focus on dividend stocks [1] - It mentions a live video series called the Underdog Daily Dividend Show, which features potential portfolio candidates [1] - The content encourages audience engagement by inviting comments on stock tickers for future reports [1]

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analyti. ...

Core Viewpoint - Agilent Technologies Inc. has received FDA approval for PD-L1 IHC 22C3 pharmDx as the only FDA-approved companion diagnostic for identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 and may be eligible for treatment with KEYTRUDA® [1] Group 1 - The FDA has approved PD-L1 IHC 22C3 pharmDx as a companion diagnostic [1] - This diagnostic is specifically indicated for patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma [1] - The approval aids in identifying patients whose tumors express PD-L1 and who may be eligible for KEYTRUDA® treatment [1]

Job Opportunities - Agilent is hiring a Sales Engineer with a Master's degree in relevant fields such as pharmaceuticals, food, environment, chemistry, biology, or materials, and requires strong communication skills and a willingness to learn [3] - Zhiming Future is looking for a Biological Analysis Instrument Sales Consultant in Shanghai, offering a salary range of 8k-13k, requiring a college degree and three years of sales experience in the biological instrument industry [4] - Beiyu Analysis is seeking Sales Representatives in multiple locations, with salary negotiable [5] - Kailai is hiring an Instrument Sales Engineer with a salary range of 15k-25k, requiring over five years of sales experience and familiarity with ICP-MS technology [7] - Tianmei Yituo is looking for a Sales Engineer in Chongqing, offering a salary of 9k-13k, requiring knowledge of various laboratory instruments [8] - Beifen Ruili is hiring a Sales Engineer in multiple cities, with a salary range of 6k-12k, requiring experience in instrument sales [10] - Yena is seeking a Sales Engineer nationwide, requiring over three years of experience in chemical analysis instruments and fluency in English [11] - Ohaus is hiring a Sales Engineer in Beijing and Nanjing, with a salary range of 11k-18k, focusing on laboratory instrument sales [15] - Steel Research Nack is looking for an ICP System Engineer in Beijing, offering a salary of 25k-30k, requiring a Master's degree and extensive experience in ICP spectrometry [26] Skills and Qualifications - Most positions require a Bachelor's degree or higher in relevant fields such as chemistry, biology, or environmental science [6][9][12] - Strong communication skills, customer service awareness, and the ability to work under pressure are commonly sought after [4][6][10] - Experience in sales, particularly in the laboratory or analytical instrument sector, is a significant advantage [7][11][26] - Many roles require the ability to travel frequently and adapt to various work environments [8][9][18]

Core Insights - Active management in short-term bonds has historically delivered returns 25% higher than passive strategies, particularly in the context of geopolitical volatility and inflation concerns in 2026 [1] - The ICE/BAML Global 1-5 Year Investment Grade Index currently yields around 4.33%, suggesting potential annual returns exceeding 5% for actively managed strategies [1] - Active bond ETFs saw record inflows of $56 billion in January, with $27 billion going into active strategies, indicating a significant shift in investor preference towards active management [1] Active Management Advantages - Active managers can achieve superior returns through strategic sector selection and "roll-down" gains as bonds approach maturity [1] - The defensive quality of active management was highlighted in 2025, where the index returned 5.49% despite challenges faced by longer-term bonds [1] - Selectivity in investment is crucial in a volatile market, with active strategies avoiding sectors like auto companies and commercial real estate that are facing rising issues [1] ETF Market Dynamics - The structure of ETFs has evolved into the "default launch vehicle" for new strategies, with active ETF assets increasing from $255 billion in 2020 to $1.3 trillion today [1] - Credit-related bond ETFs attracted $11 billion in January, reflecting a preference for targeted exposure over broad index holdings [1] - If the current pace of active bond ETF inflows continues, total assets could exceed $2 trillion, indicating a long-term shift in investment strategy [1]

Market Overview - The proteomics market was valued at USD 29.92 billion in 2025 and is projected to grow to USD 58.66 billion by 2031, with a CAGR of 11.87% from 2026 to 2031, driven by precision medicine, chronic diseases, and demand for advanced analytical tools [1] - The role of proteomic analysis is expanding in drug discovery, biomarker identification, and disease pathway analysis, enhancing target validation and supporting targeted therapies [2] Regional Analysis - North America leads the proteomics market due to strong investment in biomedical research, advanced laboratory infrastructure, and the presence of major pharmaceutical and biotechnology companies [3] - Europe holds a significant market share, supported by active research programs and a focus on personalized medicine [4] - Asia-Pacific is emerging as a high-growth region, driven by expanding research capabilities and increasing government funding for life sciences [4] Market Trends - There is a growing adoption of proteomics in drug discovery to identify disease biomarkers and improve understanding of therapeutic targets [5] - The integration of proteomics with genomics is enhancing its role in precision medicine, enabling personalized approaches to disease diagnosis and treatment [6] Industry Segmentation - The proteomics market is segmented by components, technologies, and applications, including drug discovery and development [7] - Key technologies include mass spectrometry, chromatography, and next-generation sequencing [8] Competitive Landscape - The proteomics industry consists of established life science technology providers and specialized proteomics solution companies, focusing on expanding analytical capabilities and forming strategic collaborations [9]

Company Overview - Agilent Technologies Inc. is a global leader in analytical and clinical laboratory technologies, providing a range of solutions including instruments, software, services, and expertise [1][1][1] - The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide [1][1][1] Upcoming Financial Results - Agilent will announce its financial results for the first quarter of fiscal year 2026 on February 25, 2026, after the stock market closes [1][1][1] - A conference call to discuss the results will be held at 1:30 p.m. PST on the same day, with a recording available for 90 days [1][1][1] Recent Financial Performance - For the fourth quarter of fiscal year 2025, Agilent reported revenue of $1.86 billion, exceeding revenue guidance and representing a growth of 9.4% reported and 7.2% core compared to the fourth quarter of 2024 [1][1][1] - The fourth-quarter GAAP net income was $434 million, or $1.53 per share, compared to $351 million, or $1.22 per share, in the fourth quarter of 2024 [1][1][1]